PMID- 19438598
OWN - NLM
STAT- MEDLINE
DCOM- 20090617
LR  - 20211020
IS  - 1365-2249 (Electronic)
IS  - 0009-9104 (Print)
IS  - 0009-9104 (Linking)
VI  - 156
IP  - 3
DP  - 2009 Jun
TI  - Infective dermatitis has similar immunological features to human T lymphotropic 
      virus-type 1-associated myelopathy/tropical spastic paraparesis.
PG  - 455-62
LID - 10.1111/j.1365-2249.2008.03869.x [doi]
AB  - Human T lymphotropic virus-type 1 (HTLV-1) is the causal agent of the 
      HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP), adult T cell 
      leukaemia/lymphoma and infective dermatitis associated with HTLV-1 (IDH). 
      Over-production of proinflammatory cytokines and an increase in HTLV-1 proviral 
      load are features of HAM/TSP, but the immunological basis of IDH has not been 
      established. In addition to severe cutaneous manifestations, the importance of 
      IDH relies on the observation that up to 30% of children with IDH develop HAM/TSP 
      in childhood and adolescence. In this study we determined the immune response in 
      patients with IDH measuring interleukin (IL)-4, IL-5, IL-10, interferon 
      (IFN)-gamma and tumour necrosis factor (TNF)-alpha levels as well as the HTLV-1 
      proviral load. Additionally, regulatory cytokines and anti-cytokines were added 
      to cultures to evaluate the ability of these molecules to down-modulate TNF-alpha 
      and IFN-gamma synthesis. HTLV-1 carriers and patients with HAM/TSP served as 
      controls. TNF-alpha and IFN-gamma levels were higher in IDH than in HTLV-1 
      carriers. There was no difference in IFN-gamma and TNF-alpha concentrations in 
      IDH and HAM/TSP patients. There was a tendency for higher IL-4 mRNA expression 
      and immunoglobulin E (IgE) levels in IDH than in HTLV-1 carriers, but the 
      difference did not reach statistical significance. The HTLV-1 proviral load was 
      significantly higher in IDH patients than in HTLV-1 carriers. IDH is 
      characterized by an exaggerated Th1 immune response and high HTLV-1 proviral 
      load. The similarities between the immunological response in patients with IDH 
      and HAM/TSP and the high proviral load observed in IDH provide support that IDH 
      is a risk factor for development of HAM/TSP.
FAU - Nascimento, M C F
AU  - Nascimento MC
AD  - Servico de Imunologia, Hospital Universitario Professor Edgard Santos, 
      Universidade Federal da Bahia, Salvador, Bahia, Brazil.
FAU - Primo, J
AU  - Primo J
FAU - Bittencourt, A
AU  - Bittencourt A
FAU - Siqueira, I
AU  - Siqueira I
FAU - de Fatima Oliveira, M
AU  - de Fatima Oliveira M
FAU - Meyer, R
AU  - Meyer R
FAU - Schriefer, A
AU  - Schriefer A
FAU - Santos, S B
AU  - Santos SB
FAU - Carvalho, E M
AU  - Carvalho EM
LA  - eng
GR  - D43 TW007127/TW/FIC NIH HHS/United States
GR  - D43 TW007127-05/TW/FIC NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Clin Exp Immunol
JT  - Clinical and experimental immunology
JID - 0057202
RN  - 0 (Cytokines)
RN  - 0 (RNA, Messenger)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 130068-27-8 (Interleukin-10)
RN  - 207137-56-2 (Interleukin-4)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - 82115-62-6 (Interferon-gamma)
SB  - IM
MH  - Carrier State/immunology
MH  - Cells, Cultured
MH  - Cross-Sectional Studies
MH  - Cytokines/*biosynthesis/immunology
MH  - Down-Regulation/immunology
MH  - Gene Expression
MH  - Human T-lymphotropic virus 1/isolation & purification
MH  - Humans
MH  - Immunoglobulin E/blood
MH  - Interferon-gamma/biosynthesis
MH  - Interleukin-10/blood
MH  - Interleukin-4/biosynthesis/genetics
MH  - Paraparesis, Tropical Spastic/*immunology
MH  - Proviruses/isolation & purification
MH  - RNA, Messenger/genetics
MH  - Skin Diseases, Viral/*immunology
MH  - Tumor Necrosis Factor-alpha/blood
MH  - Viral Load
PMC - PMC2691974
EDAT- 2009/05/15 09:00
MHDA- 2009/06/18 09:00
PMCR- 2010/06/01
CRDT- 2009/05/15 09:00
PHST- 2009/05/15 09:00 [entrez]
PHST- 2009/05/15 09:00 [pubmed]
PHST- 2009/06/18 09:00 [medline]
PHST- 2010/06/01 00:00 [pmc-release]
AID - CEI3869 [pii]
AID - 10.1111/j.1365-2249.2008.03869.x [doi]
PST - ppublish
SO  - Clin Exp Immunol. 2009 Jun;156(3):455-62. doi: 10.1111/j.1365-2249.2008.03869.x.